Alan Franklin, PhD
Retina Specialist · Mobile, ALNPI 1366492365
Payments from drug & device makers
Across 239 payments — averaging $742.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$130K
- Alcon$40K
- Novartis$3K
- Oculus Surgical Inc.$958
- Regeneron Healthcare Solutions, Inc.$570
- Genentech USA, Inc.$493
- plus $3K from 18 others
What the payments were for
- Consulting fees$83,28886%
- Speaking & faculty fees$8501%
- Travel & lodging$3,0723%
- Food & beverage$9,76210%
- Entertainment$2350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 27 | $130,180 |
| Alcon | 86 | $39,533 |
| Novartis | 16 | $2,696 |
| Oculus Surgical Inc. | 2 | $958 |
| Regeneron Healthcare Solutions, Inc. | 10 | $570 |
| Genentech USA, Inc. | 21 | $493 |
| Carl Zeiss Meditec USA, Inc. | 3 | $411 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $351 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $292 |
| Apellis Pharmaceuticals, Inc. | 7 | $289 |
| AbbVie(2 entities) | 6 | $251 |
| Optos, Inc. | 3 | $235 |
| Bausch & Lomb Americas Inc. | 12 | $223 |
| Kala Pharmaceuticals, Inc. | 10 | $178 |
| Astellas Pharma US Inc | 8 | $172 |
| Alimera Sciences, Inc. | 4 | $146 |
| Carl Zeiss Meditec, Inc. | 1 | $137 |
| Eyevance Pharmaceuticals LLC | 1 | $105 |
| Neurotech Pharmaceuticals, Inc. | 1 | $86 |
| Amgen(2 entities) | 4 | $60 |
| Tarsus Pharmaceuticals, Inc. | 1 | $40 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| AstraZeneca | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$42,282
- Constellation$27,360
- Luxor$14,107
- AcrySof$10,500
- Alcon Greishaber Finesse$9,800
- Centurion$2,100
- EYLEA$366
- IOLMaster 700$278
- CLARUS$270
- Tecnis IOL$142
- Unity$134
- XIIDRA$125
- LOTEMAX SM$125
- CATALYS SYSTEM$124
- Syfovre$122
- EYLEA HD$122
- OZURDEX$122
- Rhopressa$119
- Rocklatan$119
- Flarex$105
How this compares
$177,469 in reported general payments places this provider in the 95th percentile of 21 retina specialist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 124 | $100,270 |
| RestasisCyclosporine | 67 | $46,257 |
| VyzultaLatanoprostene Bunod | 57 | $26,845 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 213 | $22,913 |
| Loteprednol Etabonate | 143 | $20,360 |
| ProlensaBromfenac Sodium | 41 | $18,039 |
| CombiganBrimonidine Tartrate/Timolol | 56 | $17,368 |
| Restasis MultidoseCyclosporine | 21 | $14,419 |
| IlevroNepafenac | 31 | $12,307 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $8,237 |
| Prednisolone Acetate | 230 | $8,201 |
| Bromfenac Sodium | 36 | $7,963 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 119 | $7,769 |
| Cyclosporine | 18 | $7,762 |
| Timolol Maleate | 141 | $6,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $223 | $127,115181 claims |
| AbbVieRestasis, Combigan, Restasis Multidose, Lumigan, Alphagan P | $251 | $85,482167 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa | $351 | $38,400184 claims |
| NovartisIlevro | $2,696 | $12,30731 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $18 | $8,23718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 retina specialist providers in Alabama.
Other retina specialist in Mobile
- Jeffrey FullerBirmingham$15K
- Larry BrownBirmingham$4K
- Alexander TalalightHuntsville$4K
- Andrew HsiaMontgomery$2K
- Vikram SainiHuntsville$1K
- Tyler RowseyBirmingham$1K
- Edgar ReadyHuntsville$1K
- Cary BaxterBirmingham$1K
- Tarek PersaudHuntsville$1K
- Scott DorinFlorence$919
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.